Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Diabetes Reports
Erschienen in: Current Diabetes Reports 4/2016

01.04.2016 | Other Forms of Diabetes (JJ Nolan, Section Editor)

Diabetes and Menopause

verfasst von: Carrie A. Karvonen-Gutierrez, Sung Kyun Park, Catherine Kim

Erschienen in: Current Diabetes Reports | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

During menopause, women’s body composition, sex hormone profile, and metabolic profile may change dramatically. In this review, we summarize studies examining whether the menopausal transition and physiologic factors characterizing the transition are associated with increased risk of diabetes. We review the evidence for estrogen therapy and diabetes risk and studies examining the relationship between diabetes and menarche, which represents an extension of the reproductive life span at the opposite end of the age spectrum. Although studied less extensively, the presence of type 1 or type 2 diabetes may increase the risk of ovarian failure, and we review this literature. In conclusion, we note that the evidence linking menopausal sex hormone changes with increased diabetes risk is weak, although rapid changes as observed with oophorectomy may increase risk. Further studies should investigate the contradictory effects of estrogen therapy upon hepatic and glucose metabolism in mid-life women.
Literatur
1.
Narayan KM, Boyle JP, Thompson TJ, et al. Lifetime risk for diabetes mellitus in the United States. JAMA. 2003;290(14):1884–90.CrossRefPubMed
2.•
Harlow SD, Gass M, Hall JE, et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab. 2012;97(4):1159–68. This paper provides the contemporary methodology for defining the stages of reproductive aging and makes recommendations on the future directions for staging the menopausal transition.CrossRefPubMedPubMedCentral
3.
Kim C. Does menopause increase diabetes risk? Strategies for diabetes prevention in midlife women. Womens Health. 2012;8(2):155–67.
4.
Sowers MR, Zheng H, McConnell D, et al. Follicle stimulating hormone and its rate of change in defining menopause transition stages. J Clin Endocrinol Metab. 2008;93(10):3958–64.CrossRefPubMedPubMedCentral
5.
Sowers MR, Zheng H, McConnell D, et al. Estradiol rates of change in relation to the final menstrual period in a population-based cohort of women. J Clin Endocrinol Metab. 2008;93(10):3847–52.CrossRefPubMedPubMedCentral
6.
Randolph Jr JF, Zheng H, Sowers MR, et al. Change in follicle-stimulating hormone and estradiol across the menopausal transition: effect of age at the final menstrual period. J Clin Endocrinol Metab. 2011;96(3):746–54.CrossRefPubMedPubMedCentral
7.
Sowers MR, Eyvazzadeh AD, McConnell D, et al. Anti-mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. J Clin Endocrinol Metab. 2008;93(9):3478–83.CrossRefPubMedPubMedCentral
8.
Rosen MP, Johnstone E, McCulloch CE, et al. A characterization of the relationship of ovarian reserve markers with age. Fertil Steril. 2012;97(1):238–43.CrossRefPubMedPubMedCentral
9.
van Rooij IA, Broekmans FJ, Scheffer GJ, et al. Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril. 2005;83(4):979–87.CrossRefPubMed
10.
de Vet A, Laven JS, de Jong FH, et al. Antimüllerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril. 2002;77(2):357–62.CrossRefPubMed
11.
Ledger WL. Clinical utility of measurement of anti-mullerian hormone in reproductive endocrinology. J Clin Endocrinol Metab. 2010;95(12):5144–54.CrossRefPubMed
12.
Lauritsen M, Bentzen J, Pinborg A, et al. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-mullerian hormone. Hum Reprod. 2014;29(4):791–801.CrossRefPubMed
13.
Heianza Y, Arase Y, Kodama S, et al. Effect of postmenopausal status and age at menopause on type 2 diabetes and prediabetes in Japanese individuals: Toranomon Hospital Health Management Center Study 17 (TOPICS 17). Diabetes Care. 2013;36(12):4007–14.CrossRefPubMedPubMedCentral
14.
Di Donato P, Giulini NA, Bacchi Modena A, et al. Risk factors for type 2 diabetes in women attending menopause clinics in Italy: a cross-sectional study. Climacteric. 2005;8(3):287–93.CrossRefPubMed
15.
Muscelli E, Kozakova M, Flyvbjerg A, et al. The effect of menopause on carotid artery remodeling, insulin sensitivity, and plasma adiponectin in healthy women. Am J Hypertens. 2009;4:364–70.CrossRef
16.
Monterrosa-Castro A, Blumel JE, Portela-Buelvas K, et al. Type II diabetes mellitus and menopause: a multinational study. Climacteric. 2013;16:663–72.CrossRefPubMed
17.
Lee JS, Hayashi K, Mishra G, et al. Independent association between age at natural menopause and hypercholesterolemia, hypertension, and diabetes mellitus: Japan nurses’ health study. J Atheroscler Thromb. 2013;20(2):161–9.CrossRefPubMed
18.
Soriguer F, Morcillo S, Hernando V, et al. Type 2 diabetes mellitus and other cardiovascular risk factors are no more common during menopause: longitudinal study. Menopause. 2009;16(4):817–21.CrossRefPubMed
19.
Mishra GD, Carrigan G, Brown WJ, et al. Short-term weight change and the incidence of diabetes in midlife: results from the Australian Longitudinal Study on Women’s Health. Diabetes Care. 2007;30(6):1418–24.CrossRefPubMed
20.
21.
Malacara JM, Huerta R, Rivera B, et al. Menopause in normal and uncomplicated NIDDM women: physical and emotional symptoms and hormone profile. Maturitas. 1997;28(1):35–45.CrossRefPubMed
22.
Appiah D, Winters SJ, Hornung CA. Bilateral oophorectomy and the risk of incident diabetes in postmenopausal women. Diabetes Care. 2014;37(3):725–33.CrossRefPubMed
23.•
Brand JS, van der Schouw YT, Onland-Moret NC, et al. Age at menopause, reproductive life span, and type 2 diabetes risk: results from the EPIC-InterAct study. Diabetes Care. 2013;36(4):1012–9. This is a subcohort analysis of the larger EPIC study, reference 25. CrossRefPubMedPubMedCentral
24.
Luborsky JL, Meyer P, Sowers MF, et al. Premature menopause in a multi-ethnic population study of the menopause transition. Hum Reprod. 2003;18(1):199–206.CrossRefPubMed
25.••
Brand JS, Onland-Moret NC, Eijkemans MJ, et al. Diabetes and onset of natural menopause: results from the European Prospective Investigation into Cancer and Nutrition. Hum Reprod. 2015;30(6):1491–8. This is the largest prospective study examining the association between diabetes and age at natural menopause. CrossRefPubMed
26.
Qiu C, Chen H, Wen J, et al. Associations between age at menarche and menopause with cardiovascular disease, diabetes, and osteoporosis in Chinese women. J Clin Endocrinol Metab. 2013;98(4):1612–21.CrossRefPubMed
27.
He L, Tang X, Li N, et al. Menopause with cardiovascular disease and its risk factors among rural Chinese women in Beijing: a population-based study. Maturitas. 2012;72(2):132–8.CrossRefPubMed
28.
Lopez-Lopez R, Huerta R, Malacara JM. Age at menopause in women with type 2 diabetes mellitus. Menopause. 1999;6(2):174–8.PubMed
29.
Lejskova M, Pit’ha J, Adamkova S, et al. Bilateral oophorectomy may have an unfavorable effect on glucose metabolism compared with natural menopause. Physiol Res. 2014;63 Suppl 3:S395–402.PubMed
30.
Riant E, Waget A, Cogo H, et al. Estrogens protect against high-fat diet-induced insulin resistance and glucose intolerance in mice. Endocrinology. 2009;150(5):2109–17.CrossRefPubMed
31.
Zhu L, Martinez MN, Emfinger CH, et al. Estrogen signaling prevents diet-induced hepatic insulin resistance in male mice with obesity. Am J Physiol Endocrinol Metab. 2014;306(10):E1188–97.CrossRefPubMedPubMedCentral
32.
33.
Chen L, Zhang C, Yeung E, et al. Age at menarche and metabolic markers for type 2 diabetes in premenopausal women: the Biocycle Study. J Clin Endocrinol Metab. 2011;96(6):E1007–12.CrossRefPubMedPubMedCentral
34.
Day FR, Elks CE, Murray A, et al. Puberty timing associated with diabetes, cardiovascular disease and also diverse health outcomes in men and women: the UK Biobank study. Sci Rep. 2015;18(5):11208.CrossRef
35.
He C, Zhang C, Hunter DJ, et al. Age at menarche and risk of type 2 diabetes: results from 2 large prospective cohort studies. Am J Epidemiol. 2010;171(3):334–44.CrossRefPubMedPubMedCentral
36.
Lakshman R, Forouhi N, Luben R, et al. Association between age at menarche and risk of diabetes in adults: results from the EPIC-Norfolk cohort study. Diabetologia. 2008;51(5):781–6.CrossRefPubMed
37.
Sternfeld B, Wang H, Quesenberry Jr CP, et al. Physical activity and changes in weight and waist circumference in midlife women: findings from the Study of Women’s Health Across the Nation. Am J Epidemiol. 2004;160(9):912–22.CrossRefPubMed
38.
Davies KM, Heaney RP, Recker RR, et al. Hormones, weight change and menopause. Int J Obes Relat Metab Disord. 2001;25(6):874–9.CrossRefPubMed
39.
Davis SR, Castelo-Branco C, Chedraui P, et al. Understanding weight gain at menopause. Climacteric. 2012;15(5):419–29.CrossRefPubMed
40.
Toth MJ, Tchernof A, Sites CK, et al. Menopause-related changes in body fat distribution. Ann N Y Acad Sci. 2000;904:502–6.CrossRefPubMed
41.
Sowers M, Zheng H, Tomey K, et al. Changes in body composition in women over six years at midlife: ovarian and chronological aging. J Clin Endocrinol Metab. 2007;92(3):895–901.CrossRefPubMedPubMedCentral
42.
De Pergola G, Maldera S, Tartagni M, et al. Inhibitory effect of obesity on gonadotropin, estradiol, and inhibin B levels in fertile women. Obesity. 2006;14(11):1954–60.CrossRefPubMed
43.
44.
Nelson LR, Bulun SE. Estrogen production and action. J Am Acad Dermatol. 2001;45(3 Suppl):S116–124.CrossRefPubMed
45.
Szymczak J, Milewicz A, Thijssen JH, et al. Concentration of sex steroids in adipose tissue after menopause. Steroids. 1998;63(5-6):319–21.CrossRefPubMed
46.
Pfeilschifter J, Koditz R, Pfohl M, et al. Changes in proinflammatory cytokine activity after menopause. Endocr Rev. 2002;23(1):90–119.CrossRefPubMed
47.
Malutan AM, Dan M, Nicolae C, et al. Proinflammatory and anti-inflammatory cytokine changes related to menopause. Prz Menopauzalny. 2014;13(3):162–8.PubMedPubMedCentral
48.
Vryonidou A, Paschou SA, Muscogiuri G, et al. Mechanisms in endocrinology: metabolic syndrome through the female life cycle. Eur J Endocrinol. 2015;173(5):R153–163.CrossRefPubMed
49.
Sites CK, Calles-Escandon J, Brochu M, et al. Relation of regional fat distribution to insulin sensitivity in postmenopausal women. Fertil Steril. 2000;73(1):61–5.CrossRefPubMed
50.
Barrett-Connor E, Schrott HG, Greendale G, et al. Factors associated with glucose and insulin levels in healthy postmenopausal women. Diabetes Care. 1996;19:333–40.CrossRefPubMed
51.
Campbell AJ, Busby WJ, Horwath CC, et al. Relation of age, exercise, anthropometric measurements, and diet with glucose and insulin levels in a population aged 70 years and over. Am J Epidemiol. 1993;138:688–96.PubMed
52.
53.
Sowers MF, Zheng H, McConnell D, et al. Testosterone, sex hormone-binding globulin and free androgen index among adult women: chronological and ovarian aging. Hum Reprod. 2009;24(9):2276–85.CrossRefPubMedPubMedCentral
54.
Oh JY, Barrett-Connor E, Wedick NM, et al. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care. 2002;25(1):55–60.CrossRefPubMed
55.
Goodman-Gruen D, Barrett-Connor E. Sex hormone-binding globulin and glucose tolerance in postmenopausal women. The Rancho Bernardo study. Diabetes Care. 1997;20(4):645–9.CrossRefPubMed
56.
Golden SH, Dobs AS, Vaidya D, et al. Endogenous sex hormones and glucose tolerance status in postmenopausal women. J Clin Endocrinol Metab. 2007;92(4):1289–95.CrossRefPubMed
57.
Kalyani RR, Franco M, Dobs AS, et al. The association of endogenous sex hormones, adiposity, and insulin resistance with incident diabetes in postmenopausal women. J Clin Endocrinol Metab. 2009;94(11):4127–35.CrossRefPubMedPubMedCentral
58.
Ding EL, Song Y, Manson JE, et al. Plasma sex steroid hormones and risk of developing type 2 diabetes in women: a prospective study. Diabetologia. 2007;50(10):2076–84.CrossRefPubMed
59.
Ding EL, Song Y, Manson JE, et al. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med. 2009;361(12):1152–63.CrossRefPubMedPubMedCentral
60.
Janssen I, Powell LH, Crawford S, et al. Menopause and the metabolic syndrome: the Study of Women’s Health Across the Nation. Arch Intern Med. 2008;168(14):1568–75.CrossRefPubMedPubMedCentral
61.
Cignarella A, Kratz M, Bolego C. Emerging role of estrogen in control of cardiometabolic disease. Trends Pharmacol Sci. 2010;31(4):183–9.CrossRefPubMed
62.
Mather KM, Kim C, Christophi CA, et al. Steroid sex hormones, sex hormone binding globulin and diabetes incidence in the Diabetes Prevention Program. J Clin Endocrinol Metab. 2015;100(10):3778–86.CrossRefPubMed
63.
Buschur E, Sarma A, Pietropaolo M, et al. Self-reported autoimmune disease by sex in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes Care. 2014;37(2):E28–29.CrossRefPubMedPubMedCentral
64.
Dorman JS, Steenkiste AR, Foley TP, et al. Menopause in type 1 diabetic women: is it premature? Diabetes. 2001;50(8):1857–62.CrossRefPubMed
65.
Strotmeyer ES, Steenkiste AR, Foley Jr TP, et al. Menstrual cycle differences between women with type 1 diabetes and women without diabetes. Diabetes Care. 2003;26(4):1016–21.CrossRefPubMed
66.
Snell-Bergeon JK, Dabelea D, Ogden LG, et al. Reproductive history and hormonal birth control use are associated with coronary calcium progression in women with type 1 diabetes mellitus. J Clin Endocrinol Metab. 2008;93(6):2142–8.CrossRefPubMedPubMedCentral
67.
SEARCH for Diabetes in Youth Study Group. The burden of diabetes mellitus among U.S. youth: prevalence estimates from the SEARCH for Diabetes in Youth Study. Pediatrics. 2006;118:1510–8.CrossRef
68.
Sjoberg L, Pitkaniemi J, Harjutsalo V, et al. Menopause in women with type 1 diabetes. Menopause. 2011;18(2):158–63.PubMed
69.
Kim C, Cleary PA, Cowie CC, et al. Effect of glycemic treatment and microvascular complications on menopause in women with type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort. Diabetes Care. 2014;37(3):701–8.CrossRefPubMedPubMedCentral
70.
Yarde F, van der Schouw YT, de Valk HW, et al. Age at menopause in women with type 1 diabetes mellitus: the OVADIA study. Hum Reprod. 2015;30(2):441–6.PubMed
71.
Khalil N, Sutton-Tyrrell K, Strotmeyer ES, et al. Menopausal bone changes and incident fractures in diabetic women: a cohort study. Osteoporos Int. 2011;22(5):1367–76.CrossRefPubMedPubMedCentral
72.
Kanaya AM, Herrington D, Vittinghoff E, et al. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/Progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2003;138(1):1–9.CrossRefPubMed
73.
Margolis KL, Bonds DE, Rodabough RJ, et al. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women’s Health Initiative Hormone Trial. Diabetologia. 2004;47(7):1175–87.CrossRefPubMed
74.
Bonds DE, Lasser N, Qui L, et al. The effect of conjugated equine estrogen on diabetes incidence: the Women’s Health Initiative randomized trial. Diabetologia. 2006;49(3):459–68.CrossRefPubMed
75.
Rossi R, Origliani G, Modena MG. Transdermal 17-beta-estradiol and risk of developing type 2 diabetes in a population of healthy, nonobese postmenopausal women. Diabetes Care. 2004;27(3):645–9.CrossRefPubMed
76.
Manson JE, Rimm EB, Colditz GA, et al. A prospective study of postmenopausal estrogen therapy and subsequent incidence of non-insulin-dependent diabetes mellitus. Ann Epidemiol. 1992;2(5):665–73.CrossRefPubMed
77.
Pentti K, Tuppurainen MT, Honkanen R, et al. Hormone therapy protects from diabetes: the Kuopio Osteoporosis Risk Factor and Prevention Study. Eur J Endocrinol. 2009;160(6):979–83.CrossRefPubMed
78.
de Lauzon-Guillain B, Fournier A, Fabre A, et al. Menopausal hormone therapy and new-onset diabetes in the French Etude Epidemiologique de Femmes de la Mutuelle Generale de l’Education Nationale (E3N) cohort. Diabetologia. 2009;52(10):2092–100.CrossRefPubMedPubMedCentral
79.
Salpeter SR, Walsh JM, Ormiston TM, et al. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab. 2006;8(5):538–54.CrossRefPubMed
80.••
Xu Y, Lin J, Wang S, et al. Combined estrogen replacement therapy on metabolic control in postmenopausal women with diabetes mellitus. Kaohsiung J Med Soc. 2014;30(7):350–61. This is a meta-analysis of studies published between 2001 and 2011 which evaluated the association of hormone therapy and diabetes risk. CrossRef
81.
Espeland MA, Hogan PE, Fineberg SE, et al. Effect of postmenopausal hormone therapy on glucose and insulin concentrations. Postmenopausal Estrogen/Progestin Interventions. Diabetes Care. 1998;21(10):1589–95.CrossRefPubMed
82.
Moyer VA, U.S. Preventative Services Task Force. Menopausal hormone therapy for the primary prevention of chronic conditions: U.S. Preventative Services Task Force recommendation statement. Ann Intern Med. 2013;158(1):47–54.CrossRefPubMed
83.
Cignarella A, Bolego C. Mechanisms of estrogen protection in diabetes and metabolic disease. Horm Mol Biol Clin Investig. 2010;4(2):575–80.PubMed
84.
Hodis HN, Mack WJ. Hormone replacement therapy and the association with coronary heart disease and overall mortality: clinical application of the timing hypothesis. J Steroid Biochem Mol Biol. 2014;142:68–75.CrossRefPubMed
85.••
Pereira RI, Casey BA, Swibas TA, et al. Timing of estradiol treatment after menopause may determine benefit or harm to insulin action. J Clin Endocrinol Metab. 2015. [Epub ahead of print]. This study evaluated the hypothesized ‘timing hypothesis’ with regard to estrogen therapy and diabetes. Findings from this study may explain some of the discordant findings regarding menopause and diabetes.
Metadaten
Titel
Diabetes and Menopause
verfasst von
Carrie A. Karvonen-Gutierrez
Sung Kyun Park
Catherine Kim
Publikationsdatum
01.04.2016
Verlag
Springer US
Erschienen in
Current Diabetes Reports / Ausgabe 4/2016
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-016-0714-x

Weitere Artikel der Ausgabe 4/2016

Current Diabetes Reports 4/2016 Zur Ausgabe

Economics and Policy in Diabetes (ES Huang and A Baig, Section Editors)

The Affordable Care Act and Diabetes Diagnosis and Care: Exploring the Potential Impacts

Hospital Management of Diabetes (GE Umpierrez, Section Editor)

Intensive Glycemic Control in Cardiac Surgery

Diabetes and Pregnancy (CJ Homko, Section Editor)

Impact of Systemic Inflammation on the Progression of Gestational Diabetes Mellitus

Diabetes and Pregnancy (CJ Homko, Section Editor)

Bariatric Surgery and the Pregnancy Complicated by Gestational Diabetes

Hospital Management of Diabetes (GE Umpierrez, Section Editor)

Perioperative Glycemic Management of Patients Undergoing Bariatric Surgery

Diabetes and Pregnancy (CJ Homko, Section Editor)

Role of Medical Nutrition Therapy in the Management of Gestational Diabetes Mellitus

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise